newsAbbVie to buy neuroscience specialist Cerevel Therapeutics for $8.7bn8 December 2023 | By Caroline Peachey (European Pharmaceutical Review)AbbVie plans to acquire neuroscience specialist Cerevel Therapeutics for $45 per share, or around $8.7 billion.